HCC study

Study name:

A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE)

Eligibility:

Confirmed diagnosis of hepatocellular carcinoma (HCC) beyond up-to-7 criteria (largest tumor diameter (cm) + number of tumors ≤7)

Treatment 1:

Regorafenib plus Pembrolizumab

Treatment 2:

TACE (cTACE or DEB-TACE)

Personal Data Disclosure Disclaimer: We may collect, use, and disclose your personal data in accordance with the Personal Data (Privacy) Ordinance. Your information will be handled with care and only used for the purposes specified at the time of collection.